VTE rates not significantly reduced by apixaban in paediatric ALL or lymphoma
Apixaban does not significantly reduce the rate of venous thromboembolism relative to standard care in paediatric patients with acute lymphoblastic leukaemia or lymphoma, show data from the phase 3 PREVAPIX-ALL trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intestinal mucositis flags bloodstream infections in feverish children with leukaemia
Monitoring biomarkers of intestinal mucositis in children undergoing treatment for acute leukaemia who develop fever may identify those at risk for bloodstream infections (BSIs), Danish researchers have found.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Upfront dabrafenib plus trametinib supported for paediatric low-grade glioma
First-line treatment with dabrafenib plus trametinib is significantly more likely to achieve a response than chemotherapy for children with low-grade glioma carrying a BRAF V600 alteration, indicates a phase 2 trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Mezigdomide plus dexamethasone show ‘preliminary efficacy’ for refractory multiple myeloma
Phase 1–2 trial findings indicate that the cereblon E3 ubiquitin ligase modulator mezigdomide, given in combination with dexamethasone, could offer a novel oral regimen for patients with heavily pretreated multiple myeloma.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Second primary malignancy risk after lymphoma chemotherapy and HSCT determined
Danish researchers have quantified the risk of second primary malignancy in patients with lymphoma who are treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intra-arterial chemotherapy approach shows promise for advanced unilateral retinoblastoma
The likelihood of successful globe salvage for children with advanced unilateral retinoblastoma is higher with intra-arterial chemotherapy than with a conventional intravenous approach, randomised trial findings suggest.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Base-edited CAR T-cell therapy shows promise for relapsed, refractory childhood ALL
Base-edited chimeric antigen receptor T-cell therapy is feasible for the treatment of relapsed or refractory childhood T-cell acute lymphoblastic leukemia, suggests research published in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intracerebral polio–rhinovirus immunotherapy feasible for paediatric malignant glioma
Intracerebral recombinant polio–rhinovirus immunotherapy is feasible in children and young people with heavily pretreated, high-grade malignant glioma, suggest phase 1b trial findings published in The Lancet Child & Adolescent Health.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
‘Multihit’ gastric cancer risk from H. pylori plus cancer-predisposing variants
The presence of Helicobacter pylori alongside pathogenic variants in cancer-predisposing genes combine to increase the risk for gastric cancer, report researchers in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Haplo-SCT plus dinutuximab beta ‘feasible’ for relapsed high-risk neuroblastoma
Children with relapsed, high-risk neuroblastoma may benefit from immunotherapy with dinutuximab beta after haploidentical stem-cell transplantation, investigators write in the Journal of Clinical Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
